The ACME Laboratories Ltd. (DSE:ACMELAB)

Bangladesh · Delayed Price · Currency is BDT

83.20

+0.10 (0.12%)

At close: Aug 13, 2026

4.65% (1Y)

Market Cap	17.61B +4.7%
Revenue (ttm)	40.05B +15.3%
Net Income	2.67B +10.9%
EPS	12.60 +10.9%
Shares Out	211.60M
PE Ratio	6.60
Forward PE	n/a
Dividend	3.50 (4.21%)
Ex-Dividend Date	Nov 19, 2025

Volume	120,440
Open	83.70
Previous Close	83.10
Day's Range	82.90 - 83.70
52-Week Range	68.60 - 88.70
Beta	0.06
Analysts	n/a
Price Target	n/a
Earnings Date	Oct 15, 2026

About The ACME Laboratories

The ACME Laboratories Ltd., a pharmaceutical company, engages in the manufacturing, marketing, and distribution of generic pharmaceutical formulation products in Bangladesh. The company offers pharmaceutical products in various therapeutic areas, such as allergic disorders, analgesic, antifribinolytic, anti-infective, antiviral, artificial sweeteners, cardiovascular, central nervous system (CNS), cough and cold, diabetes, eye care and preparations, gastroprokinetic, hepatobiliary, gastrointestinal, gynaecological, hand sanitizers, hormones and ... [Read more]

Industry Pharmaceutical Preparations

Founded 1954

Employees 9,025

Stock Exchange Dhaka Stock Exchange

Ticker Symbol ACMELAB

Full Company Profile

Financial Performance

In fiscal year 2025, The ACME Laboratories's revenue was 35.94 billion, an increase of 12.54% compared to the previous year's 31.93 billion. Earnings were 2.43 billion, a decrease of -1.12%.

Financial Statements